ClinicalTrials.gg

Program

setmelanotide

Also written as “Setmelanotide”, “RM-493” and “Setmelanotide 2 mg”.

Its studies are mostly in Obesity · Sexual Infantilism · Prader-Willi Syndrome · Overweight · Hypertriglyceridemia, led by Rhythm Pharmaceuticals.

Furthest: phase 4, since Jul 30, 202122 company-led studies, 3 open or runningNext primary completion: Mar 13, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rhythm Pharmaceuticals223 open or runningphase 4since Jul 30, 2021Dec 11, 2012Mar 13, 2027phase 3 · NCT06760546

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Dec 11, 2012.

  1. Sep 14, 2017Phase 3 study in ObesityNCT03287960 · 15 enrolled · Canada, France, Germany and more
  2. Jan 18, 2018Phase 3 study in ObesityNCT03651765 · 205 enrolled · United States, Canada, France and more
  3. Nov 15, 2018Phase 3 study in Bardet-Biedl SyndromeNCT03746522 · 52 enrolled · United States, Canada, France and more
  4. Mar 30, 2020Phase 1 study in Renal InsufficiencyNCT04348175 · 32 enrolled · United States
  5. Jan 6, 2021Phase 2 study in Sexual InfantilismNCT04725240 · 18 enrolled · United States
  6. Mar 29, 2021Phase 3 study in Bardet-Biedl SyndromeNCT04966741 · 12 enrolled · United States, Australia, Spain and more
  7. Jun 28, 2021Phase 2 study in Genetic ObesityNCT04963231 · 164 enrolled · United States, Canada, Germany and more
  8. Jul 27, 2021Phase 3 study in Bardet-Biedl SyndromeNCT05194124 · 19 enrolled · United States, Canada, Germany and more
  9. Jul 30, 2021Phase 4 study in HealthyNCT05046132 · 77 enrolled · United States
  10. Sep 30, 2021Phase 3 study in ObesityNCT05093634 · 296 enrolled · United States, Canada, France and more
  11. Mar 1, 2023Phase 3 study in Sexual InfantilismNCT05774756 · 143 enrolled · United States, Canada, Germany and more
  12. Sep 10, 2024Phase 3 study in ObesityNCT06596135 · 28 enrolled · United States
  13. Dec 31, 2024Phase 3 study in Sexual InfantilismNCT06760546 · 39 planned · United States, United Kingdom
  14. Jan 10, 2025Phase 2 study in Prader-Willi SyndromeNCT06772597 · 18 enrolled · United States

Ahead

  1. Nov 3, 2026Primary completion: phase 2 study in Prader-Willi SyndromeNCT06772597
  2. Mar 13, 2027Primary completion: phase 3 study in Sexual InfantilismNCT06760546

TargetBeta

MC4R →read by rule
“Melanocortin receptor 4 agonist; Melanocortin receptor 4 agonist”ChEMBL 37, by rule

Other programs on MC4R

ProgramCompanyFurthest phaseStudies
bremelanotiderulepalatin-technologies-incphase 48
bivamelagonruleRhythm Pharmaceuticalsphase 23
mifomelatideruleendevica-biophase 22

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06772597Prader-Willi Syndrome · United States2Active, not recruitingNov 3, 202618
NCT06760546Sexual Infantilism · United States, United Kingdom3RecruitingMar 13, 202739
NCT06596135Obesity · United States3CompletedJun 24, 202628
NCT05774756Sexual Infantilism · United States, Canada, Germany and more3Active, not recruitingMar 18, 2025143
NCT05093634Obesity · United States, Canada, France and more3CompletedDec 19, 2025296
NCT05046132Healthy · United States4CompletedApr 7, 202277
NCT05194124Bardet-Biedl Syndrome · United States, Canada, Germany and more3CompletedOct 19, 202319
NCT04963231Genetic Obesity · United States, Canada, Germany and more2CompletedAug 4, 2023164
NCT04966741Bardet-Biedl Syndrome · United States, Australia, Spain and more3CompletedSep 18, 202312
NCT04725240Sexual Infantilism · United States2CompletedJun 28, 202218
NCT04348175Renal Insufficiency · United States1CompletedApr 17, 202132
NCT03746522Bardet-Biedl Syndrome · United States, Canada, France and more3CompletedNov 16, 202052
NCT03651765Obesity · United States, Canada, France and more3CompletedJan 9, 2025205
NCT03287960Obesity · Canada, France, Germany and more3CompletedSep 25, 202015
NCT03262610Hypertriglyceridemia · United States2CompletedJan 31, 20181
NCT03013543Obesity · United States, Canada, France and more2CompletedMar 1, 2022213
NCT02896192Obesity · United States, Belgium, Canada and more3CompletedMay 25, 202015
NCT02431442Overweight1CompletedJan 201457
NCT02311673Prader-Willi Syndrome · United States2CompletedOct 26, 201640
NCT02041195Overweight · United States2CompletedAug 201499
NCT01867437Obesity · United States1CompletedMar 201415
NCT01749137Overweight · United States2CompletedSep 28, 201374

How it is read

Names in the registry

  • “Setmelanotide”, 19 entries
  • “RM-493”, 2 entries
  • “Setmelanotide 2 mg”, 1 entry
  • “Setmelanotide 2.5 mg”, 1 entry
  • “Setmelanotide 3 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.